Evaluation Report on the "Corporate Value and Return Enhancement" Action Plan for 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Filed with SSE · · 3 pages · Chinese
The report highlights the company's focus on improving operational quality and enhancing core competitiveness through innovation and effective management strategies. It also emphasizes the company's commitment to stable profit distribution and investor returns, alongside efforts to improve information disclosure and corporate governance.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Evaluation Report on the "Corporate Value and Return Enhancement" Action Plan for 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Shaanxi Meibang Pharmaceutical Group Co., Ltd. on 6ix
Follow Shaanxi Meibang Pharmaceutical into a list and get an email when it puts out news.
Follow Shaanxi Meibang Pharmaceutical